We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Gold Standard Diagnostics Launches COVID-19 Antibody Tests

By LabMedica International staff writers
Posted on 20 Apr 2020
The Gold Standard Diagnostics Group {(GSD) Davis, CA, USA), which comprises Gold Standard Diagnostics Inc., VIROTECH Diagnostics GmbH, and NovaTec Immundiagnostica GmbH, have launched three different serological assays for the detection of antibodies against the novel coronavirus SARS-CoV-2, following Emergency Use Authorization (EUA) granted by the Food and Drug Administration (FDA). More...


The IgA, IgG, and IgM assays are formatted for optimal functionality in diagnostic laboratories each with a total incubation time of 90 minutes at room temperature with ready to use controls. The kits are designed to be run manually and on any open automated EIA platform. Several hundred samples were run in development studies including PCR confirmed patients, cross-reactive samples, and convalescent sample draws.

According to experts, there is a large range of applications for serologic testing. As knowledge develops about the immunity to potential re-infection of patients having previously contracted COVID-19 and recovered, antibodies testing may provide information about statistically reduced contagion risks of and from these persons. Hence, reliable detection of these antibodies will play an important role in combating the disease and preventing the spread of infections. GSD’s COVID-19 serology assays are designed to help patients and doctors and will be a valuable tool for epidemiological studies. The ability to support antibody testing should increase understanding of the disease and support health authorities in protecting the health of the population.

Related Links:
The Gold Standard Diagnostics Group


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.